Paxil CR resumes shipments
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline resumes shipments of Paxil CR, four months after manufacturing problems led to FDA's seizure of the product at distribution and production facilities. Sales reps will offer 30-day free trial vouchers to support reintroduction. Resupply of Avandamet, which also was seized by FDA, is projected to begin by mid-July...